Fluperlapine

Fluperlapine

Fluperlapine
Systematic (IUPAC) name
3-fluoro-6-(4-methylpiperazin-1-yl)-11H-dibenzo[b,e]azepine
Identifiers
CAS Registry Number  N
ATC code None
PubChem CID:
ChemSpider  YesY
UNII  YesY
ChEMBL  YesY
Chemical data
Formula C19H20FN3
Molecular mass 309.381 g/mol
 N   

Fluperlapine (NB 106-689), also known as fluoroperlapine, is a tricyclic atypical antipsychotic with additional antidepressant and sedative effects. It was first synthesized in 1979, and then subsequently studied in animals and humans in 1984 and beyond,[1] but despite demonstrating efficacy in the treatment of a variety of medical conditions including schizophrenia,[2][3][4][5] psychosis associated with Parkinson's disease,[6] depressive symptoms, and dystonia,[7] it was never marketed.[1] This was perhaps due to its capacity for producing potentially life-threatening agranulocytosis, similarly to clozapine,[8] which it closely resembles both structurally and pharmacologically.

Binding profile[9]
Receptor Ki (nM)
5-HT2A 7.9
5-HT2C 18.2
5-HT6 29
5-HT7 4.6
M1 8.8
M2 71
M3 41
M4 14
M5 17
D1 85
D2 316.2
D3 254.7
D4 21

See also

References

  1. ^ a b
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^